HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Brii Biosciences - Insights on Pipeline and Related Concerns

Pre-IPO Shanghai Hanyu Medical Technology - Insights on the Industry and the Products

Pre-IPO MicroTech Medical (Hangzhou) - The Main Products, the Business and the Challenges

China Healthcare Policy Update - The Official Results of 2020 Medical Insurance Negotiations

Insights On China Healthcare Policy - 4+7: New Volume-Based Purchasing Policy

I-Mab (IMAB US) - Insights On Core Products TJC4, TJ202 and TJ101

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Changchun High & New Tech A / Equity Bottom-Up

<p>Recently, <a href="https://www.smartkarma.com/entities/changchun-high-new-technology-industry-group-inc-a" target="_blank" data-smartkarma-citation="entities:1371:1" rel="noopener">Changchun High &amp; New Tech A (000661 CH)</a> (CCHT) 's share price has fallen continuously, down 13.3% in last three trading days from May 21 to May 25, which was quite rare and has already caused alert from investors. This insight mainly analyzed the potential reasons of the recent pullback and the future business outlook.</p>

Recently, Changchun High &amp; New Tech A (000661 CH) (CCHT) 's share price has fallen continuously, down 13.3% in last three trading days from May 21 to May 25, which was quite rare and has already caused alert from investors. This insight mainly analyzed the potential reasons of the recent pullback and the future business outlook.

Changchun High & New Tech (000661.CH) - Insights on Recent Pullback & The Future Business Outlook